IOVA vs NVS
IOVA: Iovance is a pioneer in tumor infiltrating lymphocyte (TIL) cell therapy, offering the first one-time, individualized T cell treatment for advanced solid tumor cancers. NVS: Novartis is a leading global pharmaceutical company focused on discovering and developing innovative, high-efficacy medicines across oncology, immunology, and neuroscience.
Side-by-side fundamentals
| Metric | IOVA | NVS | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $13.31 | $143.11 | |
| Market cap | $6.0B | $227.4B | |
| P/E as of 2026-09-03 | n/a | 21.95 | |
| Net margin FY2025, SEC XBRL | -148.4% | n/a | |
| Operating margin FY2025, SEC XBRL | -153.1% | n/a | |
| ROE FY2025, SEC XBRL | -56.0% | +30.0% | NVS higher |
| ROA FY2025, SEC XBRL | -42.8% | +12.6% | NVS higher |
| Debt / equity as of 2026-09-02 | 0.00 | 1.18 | IOVA lower |
| Revenue growth (YoY) as of 2026-09-02 | +34.5% | +3.3% | IOVA higher |
| Revenue CAGR (3y) SEC XBRL | +1388.7% | n/a | |
| Dividend yield as of 2026-09-03 | n/a | +3.4% | |
| Dividend streak (yrs) SEC XBRL | 0 | n/a | |
| Beta as of 2026-09-02 | 1.52 | 0.23 | |
| 1-year return as of 2026-10-08 close | +486.3% | +8.2% | IOVA higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.